Physician profile
David Arluck
NPI 1508963240
$2,434.95
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $242 · 2021: $596 · 2022: $532 · 2023: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.03 | 2019-2022 | |
| Boston Scientific Corporation | $315.17 | 2019-2023 | |
| Allergan, INC. | $298.87 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $226.02 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $185.10 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $168.71 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $163.21 | 2021-2022 | |
| Atricure, INC. | $150.25 | 2022 | |
| Amgen INC. | $124.09 | 2019 | |
| Sanofi-Aventis U.S. LLC | $121.43 | 2019 | |
| Cardiovascular Systems INC. | $92.86 | 2019 | |
| Abbvie INC. | $85.23 | 2023 | Dalvance, Avycaz, Teflaro |
| E.R. Squibb & Sons, L.L.C. | $44.61 | 2020-2022 | |
| Abbott Laboratories | $42.12 | 2021 | |
| Amarin Pharma, INC. | $17.14 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.87 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Arluck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.